Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $196M | $179M | $212M | $235M | $203M | $305M | $428M |
| Revenue growth | — | -8.6% | 18.3% | 10.6% | -13.7% | 50.8% | 40.0% |
| Gross profit | $82.8M | $4.03M | -$16.6M | -$26.8M | $90.0M | $194M | $298M |
| Gross margin | 42.2% | 2.2% | -7.8% | -11.4% | 44.4% | 63.6% | 69.7% |
| Operating income | -$30.4M | -$242M | -$446M | -$668M | -$181M | -$23.2M | -$13.1M |
| Operating margin | -15.5% | -134.9% | -210.3% | -284.5% | -89.2% | -7.6% | -3.1% |
| Net income | -$29.7M | -$241M | -$245M | -$549M | -$176M | -$52.3M | -$21.0M |
| Net margin | -15.1% | -134.6% | -115.6% | -233.9% | -86.8% | -17.1% | -4.9% |
| EPS (diluted) | -$264,056.00 | -$47,036.00 | -$2.27 | -$53.63 | -$7.23 | -$1.94 | -$0.73 |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$18.7M | -$93.1M | -$190M | -$319M | -$180M | -$28.5M | $33.3M |
| Capital expenditures | $11.9M | $24.1M | $9.40M | $7.16M | $5.25M | $5.49M | $19.0M |
| Free cash flow | -$30.7M | -$117M | -$200M | -$326M | -$185M | -$34.0M | $14.3M |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $115M | $108M | $401M | $124M | $99.7M | $85.2M | $105M |
| Total assets | — | $252M | $554M | $491M | $419M | $419M | $524M |
| Total liabilities | — | $247M | $166M | $237M | $191M | $174M | $216M |
| Long-term debt | — | $19.0M | $11.0M | $6.25M | $52.7M | $51.9M | $48.2M |
| Shareholders' equity | -$88.7M | -$330M | $388M | $254M | $228M | $245M | $308M |
| Retained earnings | — | -$330M | -$575M | -$1.12B | -$1.30B | -$1.35B | -$1.37B |
| Shares (wtd avg diluted) | 124M | 5.13B | 108M | 10.2M | 24.3M | 26.9M | 28.6M |
Every figure is extracted from GeneDx Holdings Corp.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.